Showing posts with label magnetic resonance. Show all posts
Showing posts with label magnetic resonance. Show all posts

13 May, 2016

Siemens partners with Case Western to develop MR Fingerprinting

At the 24th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM) in Singapore, Case Western Reserve University and Siemens Healthcare will announce an exclusive research partnership to further develop a quantitative imaging method known as Magnetic Resonance Fingerprinting (MRF). Researchers at the Cleveland, Ohio, (USA) university and Siemens' developers will further refine this highly promising method of quantitative tissue analysis.



"We have been working with Siemens for over 30 years, developing and applying emerging MRI technologies, and we are excited to continue this great partnership," says Mark Griswold, PhD, professor of radiology at Case Western Reserve and program chair at this year's ISMRM. "We are very proud and excited to be the exclusive partner of Case Western Reserve University to further develop MR Fingerprinting," comments Dr. Christoph Zindel, head of the business line Magnetic Resonance at Siemens Healthcare. "The most innovative applications can only be brought to life through the collaborative efforts of industry and research," says Zindel. "The goal of MR Fingerprinting is to specifically identify and characterize individual tissues and diseases," states Griswold. "But to try to get there, we've had to rethink a lot of what we do in MRI."

MRF is an innovative, highly versatile and insightful method of measurement, intended to provide non-invasive, user- and scanner-independent quantification of tissue properties. The MRF method is designed to measure a wide range of parameters simultaneously, quantifying many important tissue properties.

Presently, the evaluation of MR images is generally qualitative. In doing so, the properties of the pathology are determined by observing differences in contrast between tissues, instead of being based on absolute measurements of individual tissue properties. Quantitative approaches exist, involving the measurement of diffusion, fat/iron deposits, perfusion or relaxation times, for example. But these sequences often require significant amounts of scan time, and the results vary depending on the scanner and the user. Given the potential low level of variance across a large number of examinations and its expected reproducibility across scanners and in different institutions, MRF could achieve more accurate monitoring and evaluation of patient treatment.

More information can be found from Siemens website by clicking here.

25 April, 2016

Profound Medical receives CE Mark for minimally invasive therapy in prostate care

Profound Medical announced that the company has received CE Mark approval for the commercial sale of TULSA-PRO.
“Our innovation and passion for this unique therapy has been recognized with the achievement of CE Mark. This is a major step forward in the growth of the company, facilitating the commercial launch of TULSA-PRO in Europe and other CE Mark jurisdictions. We expect this approval to be a catalyst for the adoption of our therapy, which has the potential to make a significant impact on the clinical community and, ultimately, patients being treated with TULSA-PRO,” said Steve Plymale, CEO.

Profound’s novel technology combines real-time Magnetic Resonance (MR) imaging with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology.TULSA-PRO has demonstrated accurate and precise ablation of prostate tissue, both malignant and benign, while providing a favourable safety profile and a low rate of erectile dysfunction.

Profound Medical GmbH, a subsidiary of Profound Medical Corp., has been established in Hamburg, Germany to support European commercial operations. The commercial launch of TULSA-PRO in Europe and other CE Mark jurisdictions will commence immediately.

Product information can be found from Profound Medical website by clicking here.

16 March, 2016

St. Jude obtains CE approval for MRI Compatible Nanostim Leadless Pacemaker

St. Jude announced CE Mark approval for magnetic resonance (MR) conditional labeling for 1.5 T scans for the company’s Nanostim™ leadless pacemaker. With the approval, throughout Europe both existing patients implanted with a Nanostim leadless pacemaker and new patients receiving a Nanostim leadless pacemaker in the future can safely undergo full-body MRI diagnostic scans.
Product information could be found from this link.

Further news: FDA Approves World's Smallest yet Leadless Pacemaker